Adverse drug events caused by three high-risk drug-drug interactions in patients admitted to intensive care units: a multicentre retrospective observational study
Klopotowska, Joanna E; Leopold, Jan-Hendrik; Bakker, Tinka; Yasrebi-de Kom, Izak; Engelaer, Frouke M; de Jonge, Evert; Haspels-Hogervorst, Esther K; van den Bergh, Walter M; Renes, Maurits H; Jong, Bas T; Kieft, Hans; Wieringa, Andre; Hendriks, Stefaan; Lau, Cedric; van Bree, Sjoerd H W; Lammers, Hendrick J W; Wierenga, Peter C; Bosman, Rob J; de Jong, Vincent M; Slijkhuis, Mirjam; Franssen, Eric J F; Vermeijden, Wytze J; Masselink, Joost; Purmer, Ilse M; Bosma, Liesbeth E; Hoeksema, Martin; Wesselink, Elsbeth; de Lange, Dylan W; de Keizer, Nicolette F; Dongelmans, Dave A; Abu-Hanna, Ameen
(2024) British Journal of Clinical Pharmacology, volume 90, issue 1, pp. 164 - 175
(Article)
Abstract
Aims: Knowledge about adverse drug events caused by drug–drug interactions (DDI-ADEs) is limited. We aimed to provide detailed insights about DDI-ADEs related to three frequent, high-risk potential DDIs (pDDIs) in the critical care setting: pDDIs with international normalized ratio increase (INR+) potential, pDDIs with acute kidney injury (AKI) potential, and
... read more
pDDIs with QTc prolongation potential. Methods: We extracted routinely collected retrospective data from electronic health records of intensive care units (ICUs) patients (≥18 years), admitted to ten hospitals in the Netherlands between January 2010 and September 2019. We used computerized triggers (e-triggers) to preselect patients with potential DDI-ADEs. Between September 2020 and October 2021, clinical experts conducted a retrospective manual patient chart review on a subset of preselected patients, and assessed causality, severity, preventability, and contribution to ICU length of stay of DDI-ADEs using internationally prevailing standards. Results: In total 85 422 patients with ≥1 pDDI were included. Of these patients, 32 820 (38.4%) have been exposed to one of the three pDDIs. In the exposed group, 1141 (3.5%) patients were preselected using e-triggers. Of 237 patients (21%) assessed, 155 (65.4%) experienced an actual DDI-ADE; 52.9% had severity level of serious or higher, 75.5% were preventable, and 19.3% contributed to a longer ICU length of stay. The positive predictive value was the highest for DDI-INR+ e-trigger (0.76), followed by DDI-AKI e-trigger (0.57). Conclusion: The highly preventable nature and severity of DDI-ADEs, calls for action to optimize ICU patient safety. Use of e-triggers proved to be a promising preselection strategy.
show less
Download/Full Text
Keywords: adverse drug events, drug–drug interactions, intensive care, patient safety, triggers, Pharmacology (medical), Pharmacology, Journal Article
ISSN: 0306-5251
Publisher: Wiley-Blackwell
Note: Funding Information: This study was funded by The Netherlands Organisation for Health Research and Development (ZonMw project number: 836041019). The funder had no role in the design of the study or writing the manuscript. Funding information Publisher Copyright: © 2023 The Authors. British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.
(Peer reviewed)